Onkologie. 2016:10(2):80-86 | DOI: 10.36290/xon.2016.019
Treatment of gastrointestinal stromal tumour
- Onkologická klinika UK a 2. LF a FN Motol, Praha
Gastrointestinal stromal tumour is the most frequent non-epithelial tumour of the gastrointestinal tract. In recent years, there has
been a very rapid progress in the options of its systemic treatment. The efficacy of biological agents in palliative indication has
been the reason for their introduction even in the adjuvant setting. Imatinib is the mainstay of the first palliative line as well as
of the adjuvant indication in high-risk resected GISTs. Following its failure in the initial dose, its escalation is recommended and
only subsequently treatment with other biological agents, such as sunitinib or regorafenib. There is a whole range of agents that
were or currently are investigated in clinical trials.
Keywords: gastrointestinal stromal tumour, imatinib, sunitinib, regorafenib, C-KIT receptor
Published: May 1, 2016 Show citation
References
- Blanke C, Demetri G, et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. NEJM 2002; 347: 472-480.
Go to original source... 
Go to PubMed... - Data on file, Novartis UK Ltd. Study No STI571B2222. Open, randomized, phase II study of Glivec in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing c-kit. Report 15th December 2003.
- Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY. Progression free survival in gastrointestinal stromal tumor with high a low dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134. Go to original source... Go to PubMed...
- Rankin C, Von Mehren M, Blanke C, Benjamin R, Fletcher ClD, Bramwell V. Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study S0033 (abstract 9005), Proc ASCO 2004; 23: 815. Go to original source...
- Van Glabbeke M, Verweij J, et al. Initial and late resistance to imatinib in advanced gastro-intestinal stromal tumor are predicted by different prognostic factors, an eortc-isg-agitg study. J Clin Oncol 2005; 23: 5795-5804. Go to original source... Go to PubMed...
- Blay JY, Le Cesne A, et al. Prospective Multicenter Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarmoma Group. J Clin Oncol 25: 1107-1113. Go to original source... Go to PubMed...
- Rios M, La Cesne A, et al. Interruption of imatinib in GIST patients with advanced diasease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. ASCO Ann Meet 2007, abstract 10016. Go to original source...
- Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta - metaanalysis based on 1.640 patients. ASCO Ann Meet 2007, abstract 10004. Go to original source...
- Chandrajit PR, DeMatteo RP. Prognostic Factors for Primary GIST: Prime Time for Personalized Therapy? Annals of Surgical Oncology 15(1): 4-6.
- Demetri GD, van Oosterom AT, et al. Efficacy and safety of sunitinib in patients with advanced gastointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006: 6736-6746. Go to original source... Go to PubMed...
- Heindrich MC, Maki RG, Corless CL, et al. Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFR mutation status. J Clin Oncol 2006; 24: 9502. Go to original source...
- Rutkowski P, Bylina E, Klimczak T, Switaj T, Limon J, et al. The outcome and predictive factors of sunitinib in advanced gastrointestinal stromal tumor (GIST) after imatinib failure - one institution study. BMC Cancer, 2012; 12: 107. Go to original source... Go to PubMed...
- Demetri GD, Reichardt P, Kang YK, Blay JY. Behalf of GRID Investigators: Randomized Phase III Trial of Regorafenib in Patients (pts) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at least Imatinib (IM) and Sunitinib (SU): The GRID Trial.
- ENESTg1 - A Randomized, Open-Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST). http://clinicaltrials.gov/show/NCT00785785.
- An Open - label, Multi-center, Single Arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment. http://clinicaltrials.gov/ct2/show/NCT00756509.
- Randomized Phase III Trial Comparing Nilotinib 800 mg Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumor Refractory to Imatinib 400 mg. http://clinicaltrials.gov/ct2/show/NCT00751036.
- A Phase II, Open-Label Study of PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST) Resistant to Imatinib Mesylate. http://clinicaltrials.gov/ct2/show/study/NCT00117299.
- Phase 2 Study of Oral AB1010 in Non Pre-Treated, Inoperable Patients With Locally Advanced / Metastatic Gastro-intestinal Stromal Tumor (GIST). http://clinicaltrials.gov/ct2/show/NCT00998751.
- An Open Label Study of AMG 706 in Subject With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate. http://clinicaltrials.gov/ct2/show/NCT00089960.
- An Open Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by (F 18) Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumors (GISTs) Resistant or Intolerant to Imatinib Mesylate. http://clinicaltrials.gov/ct2/show/study/NCT00385203
- An Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GISTs) Who Failed to Imatinib and Sunitinib http://clinicaltrials.gov/ct2/show/NCT01091207.
- Demetri GD. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial. 2007 ASCO Annual Meeting, Sarcoma. Go to original source...
- A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) http://clinicaltrials.gov/ct2/show/NCT010339519.
- Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. A Multi Center Phase II Trial. http://clinicaltrials.gov/ct2/show/NCT00568750.
- Van Oosterom AT, Dumez H, Desai J, et al. Combination signal transduction inhibition: A phase I/II trial of the oral m-TOR-inhibitor everolimus (E, RAD001) and imatinib mesylate in patients with gastrointestinal stromal tumors refractory to imatinib mesylate. J Clin Oncol 2004; 22: 3002. Go to original source...
- Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions, Including the D842V Mutation, in the PDGFRA Gene. http://clinicaltrials.gov/ct2/show/NCT01243346.
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumor http://clinicaltrials.gov/ct2/show/NCT0133184.
- A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma http://clinicaltrials.gov/ct2/show/NCT000997765.
- De Matteo RP, Antonescu CR, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000; ASCO 2008.
- De Matteo RP, Owzar K, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001; ASCO 2008.
- Scandinavian Sarcoma Group. Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). SSGXVIII/AIO. http://www.clinicaltrials.gov/ct/show/NCT00116935?order=1. Accessed October 25, 2007.
- European Organisation for Research and Treatment of Cancer. Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor - EORTC-62024. http://www.clinicaltrials.gov/ct/show/NCT00103168?order=1. Accessed October 25, 2007.
- A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Years Adjuvant Imatinib Mesylate (Gleevec(R)) in Patients at Significant Risk of Recurrence Following Complete Resection nof Primary Gastrointestinal Stromal Tumor (GIST) http://clinicaltrials.gov/ct2/show/NCT00867113.
- Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steiger SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordori A, Magnusson ML, Linke Z, Sufliarsky J, Frederico M, Jonnsson JG, Dei Tos AP, Rutkowski P. Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled-based cohorts. The Lancet Oncology 2012; 13(3): 265-274. Go to original source... Go to PubMed...
- Kocakova I, Kocak I, Spelda S, Krejci E, Bencikova B, Jureckova A, Vyzula R, Bortlicek Z, Strenkova J, Brabec P. Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumors. Bratislava Medical Journal 2015; 116(4): 218-221. Go to original source... Go to PubMed...